Rein Therapeutics (RNTX) Cash from Financing Activities (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Cash from Financing Activities of $4.7 million for Q1 2026, up 530.62% year-over-year from $738000.0 in Q1 2025, and up 93.51% quarter-over-quarter from $2.4 million in Q4 2025.
Rein Therapeutics (RNTX) Cash from Financing Activities (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Cash from Financing Activities for 10 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 530.62% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $13.7 million (down 26.33% YoY), while the FY2025 annual figure was $9.8 million, down 45.25% from the prior year.
- Cash from Financing Activities grew to $4.7 million in Q1 2026 per RNTX's latest filing, from $2.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $18.3 million in Q2 2024 and bottomed at -$446000.0 in Q3 2024.
- Historically, Cash from Financing Activities has averaged $5.3 million across 4 years, with a median of $2.4 million in 2025.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities sank 99.99% — and 2025, when it jumped 240400.0%.
- Rein Therapeutics' Cash from Financing Activities stood at $15.8 million in 2023, then tumbled by 99.99% to $1000.0 in 2024, then surged by 240400.0% to $2.4 million in 2025, then jumped by 93.51% to $4.7 million in 2026.
- Business Quant data shows RNTX's Cash from Financing Activities at $4.7 million in Q1 2026, $2.4 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 47.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.82 Mn |
| Jun 30, 2026 | 47.82 Mn |
| Mar 31, 2026 | 4.65 Mn |
| Mar 31, 2026 | 4.65 Mn |
| Dec 31, 2025 | 2.41 Mn |
| Dec 31, 2025 | 2.41 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 4.71 Mn |
| Jun 30, 2025 | 4.71 Mn |
| Mar 31, 2025 | 738,000.00 |
| Mar 31, 2025 | 738,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | -446,000.00 |
| Sep 30, 2024 | -446,000.00 |
| Jun 30, 2024 | 18.26 Mn |
| Jun 30, 2024 | 18.26 Mn |
| Dec 31, 2023 | 15.79 Mn |
| Dec 31, 2023 | 15.79 Mn |